Authors

Elisabeth I. Heath, MD, FACP

Latest:

Dr. Heath on Developments in Nonmetastatic CRPC

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Kyle Doherty

Latest:

Celularity and Imugene Enter into Potentially ‘Game-Changing’ Collaboration

Chimeric antigen receptor T-cell therapies are rapidly shifting the treatment paradigm for a multitude of hematologic malignancies.

Jared Weiss, MD, University of North Carolina at Chapel Hill

Latest:

Emerging Agents and Future of Small Cell Lung Cancer

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Bradley Corr, MD

Latest:

Dr. Corr on the Rationale to Evaluate WNT Inhibition in Gynecologic Cancers

Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.

Larysa J. Sanchez, MD

Latest:

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Michael R. Grunwald, MD, FACP

Latest:

Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL Treatment

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

John F. Lazar, MD

Latest:

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

IU School of Medicine

Latest:

IU School of Medicine names new cancer center director, announces $15 million supporting gift from Walther Cancer Foundation

Indiana University School of Medicine has announced the hiring of a world-recognized medical oncologist and multiple myeloma researcher to lead the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Daniel C. Danila, MD

Latest:

Dr. Danila on Considerations for Treatment Selection in Nonmetastatic CRPC

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

Antonia DePace

Latest:

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Sponsored by Bristol Myers Squibb

Doug Smith, MD, John Hopkins Medicine

Latest:

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Namrata (Neena) Vijayvergia, MD

Latest:

Dr. Vijayvergia on the Efficacy of Pembrolizumab in MSI-H Advanced Gastric Cancer

Namrata (Neena) Vijayvergia, MD, discusses the efficacy of pembrolizumab with or without chemotherapy in patients with microsatellite instability–high advanced gastric cancer.

Michael Blackman, MD

Latest:

Patient Experiences Can Affect a Practice’s Financial Health

The patient experience is a critical factor in the success of any healthcare practice, and its importance is increasing with the rise of health care consumerism.

Ahmet Sezer, MD

Latest:

Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 Expression

Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.

Salvatore Siena, MD

Latest:

Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Phillip Palmbos, MD, PhD

Latest:

Dr. Palmbos on Remaining Questions in Metastatic Urothelial Carcinoma

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Sandip P. Patel, MD, UC San Diego Health

Latest:

Treatment of Advanced NSCLC With Immune Checkpoint Inhibitors

Drs Vamsidhar Velcheti, Ani Balmanoukian, Heather Wakelee, and Stephen Liu discuss recent updates on single-agent immunotherapy regimens in patients with NSCLC.

Mohammed M. Milhem, MBBS

Latest:

Dr. Milhem on Design of Phase 1b/2 Study With AST-008 in CSCC

Mohammed M. Milhem, MBBS, discusses the design of an open-label, multicenter phase 1b/2 dose escalation/expansion study with AST-008 in combination with a PD-1 inhibitor, such as pembrolizumab or cemiplimab, in Merkel cell carcinoma and cutaneous squamous cell carcinoma.

John Zalcberg, PhD, OAM

Latest:

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.